Development of In-vitro Assays to Estimate Rabies Viral Protein in Vaccine Preparation

Thangaraj Sekar, Ganesan Chandra Mohan, Citrambalam Palaniappan, Ananda Arone Premkumar, Bheeman Sundaran and Balaraman Sekar

Pasteur Institute of India, Coonoor, The Nilgiris, Tamilnadu, India

*Corresponding author: Thangaraj Sekar, Assistant Research Officer, Pasteur Institute of India, Research and Development, Coonoor, Tamilnadu 643103, India, Tel: +9487365795, E-mail: sekar_102000@yahoo.com

Received date: May 29, 2018; Accepted date: June 22, 2018; Published date: June 27, 2018

Copyright: ©2018 Sekar T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Vaccine against rabies is prepared by cell culture technology and these vaccines are free from many side effects when compared to nerve tissue vaccines. The vaccine production is a continuous process involving propagation of virus, harvesting, concentration, inactivation, purification and formulation with preservatives. The quantification of viral protein in the intermediate biological product is an in-process quality control test to reduce the product loss during various process of vaccine manufacturing. The conventional in-vivo & in-vitro tests employed for the quantification of rabies viral protein are time consuming, laborious and requires laboratory animals. In this study, we attempted to develop in-house serological methods such as sandwich ELISA, Dot Blot for the detection and quantification of rabies antigen in the intermediate biological material during vaccine preparation. The hyper immune sera samples were prepared by immunizing two animal models i.e. Guinea Pigs and rabbits with standard Rabies antigen. The sera samples were purified by saturated ammonium sulphate precipitation and further by G50 gel column. The anti-rabies antibody titre in the purified preparation was estimated using Rapid Fluorescent Focus Inhibition Test (RFFIT).

National Reference Rabies Vaccine received from Central Drug Laboratory, Kasauli was used to prepare the local reference standard and it was included in the in-house serological methods to validate the assay. Our in-house tests are found to be simple, rapid and cost effective and require less time when compared to in-vivo animal challenge and cell culture based in-vivo tests.

Keywords: Rabies vaccine; Immunization; Propagation

Introduction

Rabies is highly fatal disease of central nervous system caused by rabies virus belonging to genus Lyssavirus in the rhabdoviridae family. Rabies is one of the major causes of human mortality, annually 60,000 deaths are reported worldwide [1] and 20,000 deaths are reported in India [2]. Rabies can be prevented by effective vaccination with the combination of anti-rabies immunoglobulin [2]. Rabies vaccines produced in mammalian neural tissues (brain of adult animals such as sheep and goats, brain of suckling animals such as mouse, rat and rabbit) had been in use worldwide for many years. Their use had led to adverse reactions following immunization, such as encephalomyelitis and polynuertis [3,4].

After the recommendation of WHO to ban the use of Neural Tissue vaccine, safe and potent vaccines manufactured by cell culture techniques (involving Vero cells, human diploid cell and chick embryo fibroblast cells) cell substrate for propagation of virus) are available and used for pre and post-exposure prophylaxis against rabies [1] all around the world. The tissue culture vaccine manufacturing process involves: cell culturing, virus propagation, harvesting, concentration, inactivation, purification and formulation [5]. Estimating the rabies virus protein content in intermediate biological product will guide determine the yield of rabies viral protein and help to reduce the product loss during vaccine production. There are five major proteins in the rabies virus namely Nucleoprotein (N), Phosphoprotein (P), Matrix or Membrane protein (M), Glycoprotein (G) and RNA polymerase (L) (Mahshid). Glycoprotein and ribonucleoprotein components of inactivated rabies vaccine play an important role in conferring protection [6,7].

The use of the conventional in-vivo challenge test for quantification of Rabies viral antigen is having various drawbacks like variability in test results, long duration of time and requires large number of animals [8-10]. Implementation of the 3Rs concepts (Replacement, Reduction, Refinement of animal experiment) by the manufactures is encouraged to limit animal requirement in vaccine testing an alternative for in-vivo methods [11]. Many serological methods have been proposed by several studies as an alternative tool for the estimation of the rabies antigens [9-15]. In our study we attempted to develop in-house assays for detection of Rabies Antigens in the intermediate tissue culture derived Rabies vaccine products.

Materials and Methods

Experimental animals

The albino Guinea pig in the weight range of 250-350 gand New Zealand white rabbit in the weight range of 1.5 kg bred in Pasteur Institute of India, Coonoor breeding facility which is registered under CPCSEA (Committee for the purpose of control and supervision of experiments on animals). The animals were maintained according to the guidelines of CPCSEA and use of these laboratory animals has the approval of Institutional Animal Ethics Committee (IAEC) of Pasteur Institute of India, Coonoor.
Preparation of hyper immune serum

The sera against the rabies viral protein is the primary requirement for the development of In-house serological methods. The hyper Immune sera against rabies viral proteins were raised in two animal models-guinea pig (5 Nos.) and rabbit (2 Nos.) by immunizing the standard antigen preparations containing 8.0 IU/dose of rabies viral proteins administered at weekly intervals. The rabies viral protein content in this antigen preparation was estimated in comparison with the national reference standard received from Central Research institute (CRI), Kasauli HP, India. The 8.0 IU of rabies viral protein in each dose of immunization was finalized to get the higher concentration antibody titre in the sera to compensate loss during purification with column.

Immunization schedule: 500 μl of rabies virus antigen (8.0 IU) and 500 μl of Freund’s complete adjuvant (SigmaLot #F-5881) were mixed thoroughly using syringe. The uniformity of the antigen-adjuvant mixing was ensured when the drop did not dissociate while placing on the surface of water [16]. One ml of prepared Antigen was administered by intramuscular route into each animal models as primary dose [17-19]. For second (on 7th day) and third dose (on 14th day) of immunization 500 μl of viral antigen and 500 μl of Freund’s incomplete adjuvant (SigmaLot #F-5506) mixed properly and 1 ml was administered by subcutaneous route [20]. From fourth dose to seventh dose of immunization 500 μl of plain viral antigens were inoculated by subcutaneous route, at weekly interval.

Blood collection: One week after the fourth dose the test bleed was done by heart puncture and two weeks after the seventh dose the final bleed was done for preparation of hyper immune sera. Heart puncture method of bleeding was preferred to avoid the haemolysis and it was done by trained technical personals. The serum was carefully separated and centrifuged at 2000 rpm for 5 min to remove the cell debris.

Purification of hyper immune sera by G50 column

The sterile saturated ammonium sulphate solution was prepared and the serum samples were mixed with half the volume of saturated ammonium sulphate solutions. The pellet was collected by centrifugation at 3000 rpm for 15 min. and after 10 min incubation period at room temperature. The pellet was washed twice with sterile 0.01 M Phosphate buffer saline and finally it was dissolved in Phosphate buffer saline and subjected for column purification.

Size exclusion chromatography: The sephatax G50 beads were swelled (Drenching) overnight in sterile PBS (pH 7.4) and poured into the glass tube of 380 mm of length and 12 mm of width (inner dia). G50 matrix was packed to a height of 160 mm without any breakin the column and equilibrated with PBS. The precipitated sera was loaded at the top of the column at once and a slower flow rate was fixed. Release of the protein from the column was examined by treating a drop with uniformity of the antigen-adjuvant mixing was ensured when the drop did not dissociate while placing on the surface of water [16]. The sample was then dissolved in 0.1 ml and incubated at 37°C for 90 min in 5% CO2 atmosphere for neutralization. Then 25,000 neuroblastoma-2A cells in 50 μl were added to each well and incubated for 40-48 h in 5% CO2 atmosphere. The fluids were removed and the cells were fixed by the addition of 70% acetone in PBS and the plate was incubated at -20°C for 30 min. Anti-Rabies FITC antibody conjugate were added to each well after removing the fixative reagent and the plate was incubated for 30 min at 37°C for conjugation. The conjugation fluid was removed, the plate was washed gently with distilled water and one drop of glycerol carbonate bicharbonate buffer (pH 9.0) was added to all the wells. The fixed and stained plate was read using fluorescent microscope.

WHO reference standard rabies immunoglobulin was reconstituted to yield 2.0 IU/ml. This was incorporated in the test along with the test samples. The last dilution showing no fluorescence was taken as 100% neutralization for both WHO reference standard and test serum samples. The antibody titre of the test sample in terms of IU/ml was extrapolated in comparison with the WHO reference serum. To ensure the quantum of virus added for neutralization of each sample, back titration was performed for each test to qualify or to validate the concentration of virus added. Normal cell control and a negative serum control were also added to rule out the false positive/non-specific fluorescence. The performance of the test was declared to be qualified only when all validation criteria passed through.

Test samples

The tissue cultured viral harvest were pooled and concentrated to 10X using TFF (Tangential flow filtration) system using 100 KDA molecular weight cut-off cassettes with phosphate buffer saline recirculation. Further the concentrated biological materials were subjected for inactivation with beta propiolactone and series of downstream processes like cellular DNA removal, purification of viral protein by HPCl system, 0.22 μ filtration, formulation with preservatives and stabilizers. The inactivated samples were collected between these stages for the estimation of viral protein by serological assays because during these stages there is higher chance for the loss of inactivated rabies viral protein (product loss) which leads to reduction in yield of final vaccine.

Dot-blotting

The Dot-blotting is a solid-phase immune assay for antibody or antigen detection. 50 μl of each intermediate vaccine product samples and local reference standard were blotted on the Nitrocellulose membrane and kept at 37°C for 30 min. The membrane was blocked with 5% Bovine Albumin Fraction V (RM 1113 Himedia) in TBS with 0.05% of Tween 20. The membrane was then incubated with guinea pig hyper immune sera (Primary antibody) followed by conjugation with Alkaline Phosphatase labelled anti guinea pig anti rabbit IgG antibody conjugate (Sigma-Lot R124310) as secondary antibody and the colour was developed using BCIP & NBT substrate system. Finally the intensity of the dots was measured by spectro densitometer as OD value.

Sandwich enzyme linked immuno sorbent assay

Sandwich ELISA is highly sensitive method to detect the target of interest by sandwiching between the antibody pairs. The guinea pig raised hyper immune sera was coated on the Costar E.L.A/R.I.A high Binding Flat Bottom 96 well plate. The plate was blocked with 2% BSA in PBS containing 0.05% tween 20. 100 μl of each of the samples, PBS as blank and local reference standard were added to respective wells as
per the layout and incubated at 37°C for 2 h. The rabbit raised hyper immune sera was used as primary antibody followed by anti-rabbit-alkaline phosphatase conjugate (Sigma-#SLBK3154V) in the ratio of 1: 20,000 as conjugate. The Phosphatase substrate (pNPP) was used for the colour development and the OD value was measured at 405 nm after completing the 20 min of incubation at dark and the results were documented.

**Western Blotting**

The rabies virus protein resolved gel was used for western blotting analysis to assess the reactogenicity of the polyclonal hyper immune sera with the different proteins of the rabies virus. The viral proteins in the SDS PAGE gel was transferred to nitrocellulose membrane using Mini Trans-Blot tank (Bio-Rad) and electro blotted under 80 V for about 30 min. Upon the completion of the run, the blotting sandwich was disassembled carefully and the membrane was removed from the sandwich for further development. Further processing were done as per the protocols of Dot Blotting assay described under 2.5 above.

**Local reference standard & standard curve**

The local reference standard was prepared using the national reference standard provided by Central Drug laboratory, Kasaulli, Himachal Pradesh by NIH potency analysis in mice model. This local reference standard was included as standard in all the serological methods. In Dot-blotting and ELISA, a standard curve was developed plotting the reading of the known antigen content (Figure 2,3). The concentration of unknown samples was extrapolated using this standard curve.

**Results**

**Hyper immune serum**

Antisera against the rabies is the primary requirement for the development of serological assay for rabies viral protein. Purified preparations of rabies antigen preparation having rabies viral protein of 8 IU/0.5 ml in each dose was used in this study for raising antisera. The US Centers for Disease Control has recommended the minimum protective antibody titer as either ≥ 1:5 (using the rapid fluorescent inhibition technique) or ≥ 0.5 IU/mL (using the mouse neutralization test) [21] it was observed much higher antibody titre in both the immunized animal models. The antibody titre was measured using RFFIT method. The antibody titre in test bleed samples (one week after the fourth dose) showed in Guinea pigs ranging from 128 IU to 400 IU per ml and in the case of Rabbits it was 400 IU per ml. 100% survival rate of animals were achieved during this test bleed. At the time of final bleed (two week after the seventh dose) the guinea pig antibody ranged from 800 IU to 2400 IU per ml and the rabbit antibody was 600 IU per ml (Table 1). The details of biological intermediate sample subjected for serological analysis were well described in materials and methods chapter 2.5.

**Table 1: Antibody raise in each animal models analysed by RFFIT.**

<table>
<thead>
<tr>
<th>S.No</th>
<th>Sample ID</th>
<th>Ab titre (1 week from 4th dose)</th>
<th>Ab titre (2 week from 7th dose)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>G.Pig 1</td>
<td>≥ 128 IU/ml</td>
<td>400 IU/ml</td>
</tr>
<tr>
<td>2</td>
<td>G.Pig 2</td>
<td>≥ 128 IU/ml</td>
<td>800 IU/ml</td>
</tr>
<tr>
<td>3</td>
<td>G.Pig 3</td>
<td>400 IU/ml</td>
<td>≥ 2400 IU/ml</td>
</tr>
<tr>
<td>4</td>
<td>G.Pig 4</td>
<td>400 IU/ml</td>
<td>800 IU/ml</td>
</tr>
<tr>
<td>5</td>
<td>G.Pig Control</td>
<td>0 IU/ml</td>
<td>0 IU/ml</td>
</tr>
<tr>
<td>6</td>
<td>Rabbit 1</td>
<td>400 IU/ml</td>
<td>600 IU/ml</td>
</tr>
<tr>
<td>7</td>
<td>Rabbit 2</td>
<td>400 IU/ml</td>
<td>600 IU/ml</td>
</tr>
</tbody>
</table>

**Dot-blotting**

The concentration of rabies antigen in test samples was measured by using Dot Blot analysis (Figure 1). The local reference standard was diluted to attain different concentrations of 0.125 IU, 0.25 IU, 0.5 IU, 1 IU, 2 IU and 4 IU and one negative control was included in this test and were blotted in the upper row and the test samples were blotted in the lower row of the membrane. The OD value of the respective dot was measured using spectro densitometer are shown in Table 2. The standard graph was plotted for different concentrations of antigen standard. We observed a gradient increase in the intensity of the optical density in line with the increasing concentration of antigen (Figure 2). The antigen concentration of the test sample was determined by extrapolating the OD values on the standard graph as shown in (Table 2).
Figure 1: Dot Blot Analysis of rabies viral antigen concentration in test samples with local reference standard. (Sample ID: 1: Permeate while concentration, 2: Concentrated material-1, 3: Concentrated Material-2, 4: Protamine sulphate precipitate, 5: HPLC protocol 1, 6: HPLC protocol 2)

Table 2: Quantification of Rabies viral antigen content by Dot Blot Analysis (NC–Negative Control, CON–Concentration, OD–Optical Density, STD–Standard, IU–International Unit).

Table 3: Quantification of Rabies viral antigen content by Sandwich ELISA Analysis (NC-Negative Control, CON-Concentration, OD-Optical Density, Std. Con.-Standard Concentration, IU-International Unit).

**Sandwich ELISA**

The sandwich ELISA was performed for the different test samples along with media blank, local reference standard in different concentrations of 0.5 IU, 1 IU, 2 IU, 3 IU and 4 IU. The OD values measured at 405 nm in ELISA 96 well plate reader. A standard curve was plotted with the different concentration of standards included in this assay procedure (Figure 3). The intensity of the substrate colour was observed to be directly proportional to the concentration of the rabies antigen. The test sample rabies antigen quantity were extrapolated using the standard graph, as shown in Table 3.

**SDS–PAGE**

The protein profile of the antigen was studied by the electrophoresis using 10% SDS PAGE. Rabies Viral genome encodes five different types of proteins namely Nucleoprotein-N (55 KDa), Phosphoprotein-M1 (40 KDa), Matrix or Membrane protein-M2 (26 KDa), Glycoprotein-G...
(64 KDa) and RNA-dependent RNA polymerase-L (190 KDa). The different proteins of the rabies viral antigen were observed in the SDS-PAGE in the silver stained gel.

**Western Blotting**

The western blotting is the highly sensitive method to confirm the presence of specific protein in the sample subjected for this test. The reactivity of the raised hyper immunesera against the different antigens of the rabies virus was studied by the in-house western blotting procedure.

Four test samples were included in this method and the bands were developed by the immunochromic reaction between the rabies antigen and hyper immune sera raised. The different protein fractions of the rabies virus were clearly observed on the nitrocellulose membrane (Figure 4). This polyclonal guinea pig hyper immune sera reacted with all the rabies viral protein fractions (samples) and there is no reaction with ladder lane due to non binding of antibody with ladder protein.

**Figure 4: Western Blotting Analysis: Rabies viral specific antigens reacted with guinea pig raised polyclonal hyper immune sera (Samples ID 1: inactivated fluid, 2: Concentrated Biological material, 3: HPLC Protocol -1, 4: HPLC protocol-2).**

**Discussion**

Conventionally the in-vivo and in-vitro methods are employed for the estimation of rabies viral antigen during the intermediate steps of the vaccine production. The conventional NIH potency (in-vivo test) method has some limitation; since the test involves the use of more animals and requires 28 days time period. The Antibody Binding Test (ABT) (in-vitro) requires sophisticated cell culture lab facility. The dot blot enzyme immuno assay (serological assay) was shown to be sensitive, specific and rapid alternative method for FAT (Fluorescent Antibody Test) for the detection of rabies antigen from post-mortem brain specimens of human [17,18]. Immune capture ELISA has been recommended to estimate the rabies viral glycoprotein antigen content in the inactivated rabies antigen preparation, in a simple and rapid format, which enables better vaccine formulation [13]. The reference vaccine included in each test shall be calibrated in International Units during vaccine preparation and also it can be implemented to test the potency of final vaccine after due validation of these assay protocols. In comparison to conventional methods, our in-house methods are simple, cost effective, rapid and no animal facility and no cell culture facilities are required.

**References**


